Seguridad de la ivermectina: toxicidad y reacciones adversas en diversas especies de mamíferos

Seguridad de la ivermectina: toxicidad y reacciones adversas en diversas especies de mamíferos

Publicado 2010-05-01

Abrir | Descargar
PDF FLIP
Cómo citar
González-Canga, A., Fernández-Martínez, N., Sahagún-Prieto, A., García-Vieitez, J., Díez, M., Tamame-Martín, P., & Sierra-Vega, M. (2010). Seguridad de la ivermectina: toxicidad y reacciones adversas en diversas especies de mamíferos. Revista MVZ Córdoba, 15(2). https://doi.org/10.21897/rmvz.325
doi

https://doi.org/10.21897/rmvz.325
Dimensions
PlumX
Aránzazu González-Canga
Nélida Fernández-Martínez
Ana Sahagún-Prieto
Juan García-Vieitez
María Díez
Pedro Tamame-Martín
Matilde Sierra-Vega
Mostrar biografía de los autores

Aránzazu González-Canga

Universidad de León. Departamento de Ciencias Biomédicas. Área de Farmacología. León. España

Nélida Fernández-Martínez

Universidad de León. Departamento de Ciencias Biomédicas. Área de Farmacología. León. España

Ana Sahagún-Prieto

Universidad de León. Departamento de Ciencias Biomédicas. Área de Farmacología. León. España

Juan García-Vieitez

Universidad de León. Departamento de Ciencias Biomédicas. Área de Farmacología. León. España

María Díez

Universidad de León. Departamento de Ciencias Biomédicas. Área de Farmacología. León. España

Pedro Tamame-Martín

Matadero GYPISA-Talavera. Talavera de la Reina, Toledo

Matilde Sierra-Vega

Universidad de León. Departamento de Ciencias Biomédicas. Área de Farmacología. León. España
La ivermectina es un fármaco antiparasitario muy utilizado en Medicina Veterinaria, dado su espectro de actividad que abarca tanto endo como ectoparásitos, elevada eficacia y amplio margen de seguridad. No obstante, su administración puede dar lugar a efectos tóxicos. La mayoría de ellos derivan de la sobredosificación del compuesto, aunque también se han descrito, a dosis terapéuticas, casos de susceptibilidad extrema a los efectos neurotóxicos del fármaco en determinadas razas o subpoblaciones de animales, así como reacciones anafilácticas por la destrucción masiva de parásitos.

Visitas del artículo 2826 | Visitas PDF

Descargas

Los datos de descarga todavía no están disponibles.
  1. McKellar QA, Benchaoui HA. Avermectins and milbemycins. J Vet Pharmacol Ther 1996; 19: 331-351. http://dx.doi.org/10.1111/j.1365-2885.1996.tb00062.x
  3. Burkhart CN. Ivermectin: an assessment of its Pharmacology, Microbiology and safety. Vet Hum Toxicol 2000; 42: 30- 35.
  5. Lankas GR, Gordon LR. Toxicology. En: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag; 1989: 89-112.
  7. Marques-Santos LF, Bernardo RR, Paula E, Rumjanek VM. Cyclosporin A and trifluoperazine, two resistancemodulating agents, increase ivermectin neurotoxicity in mice. Pharmacol Toxicol 1999; 84: 125-129. http://dx.doi.org/10.1111/j.1600-0773.1999.tb00887.x
  9. Dadarkar SS, Deore MD, Gatne MM. Comparative evaluation of acute toxicity of ivermectin by two methods after single subcutaneous administration in rats. Regul Toxicol Pharmacol 2007; 47: 257-260. http://dx.doi.org/10.1016/j.yrtph.2006.10.009
  11. Schinkel AH, Smit JJM, Van Telligen O, Beijnen JH, Wagenaar E, Van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensivity to drugs. Cell 1994; 77: 491-502. http://dx.doi.org/10.1016/0092-8674(94)90212-7
  13. Schinkel AH, Wagenaar E, Van Deemter L, Mol CA, Borst P. Absence of mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethason, digoxin and ciclosporyn A. J Clin Invest 1995; 96: 1698-1705. http://dx.doi.org/10.1172/JCI118214
  15. Lankas GR, Cartwright ME, Umbenhauer DR. P-glycoprotein deficiency in a subpopulation of mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997; 143: 357- 365. http://dx.doi.org/10.1006/taap.1996.8086
  17. Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, et al. Identification of a P-glycoproteindeficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Tox Appl Pharm 1997; 146: 88-94. http://dx.doi.org/10.1006/taap.1997.8225
  19. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA, et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 1999; 27: 581-587.
  21. Leaning WHD, Roncalli RA, Brokken ES. The efficacy and safety evaluation of ivermectin: a new injectable antiparasitic agent for cattle. En: Leaning W, Siegmund O, Fraser C, eds. Recent developments in the control of animal parasites. Proceedings of the MSD AGVET Symposium at the XXII World Veterinary Congress. Perth: MSD AGVET; 1983: 25-41.
  23. Hotson IK. The development of ivermectin as an antiparasitic agent in sheep. En: Leaning W, Siegmund O, Fraser C, eds. Recent developments in the control of animal parasites. Proceedings of the MSD AGVET Symposium at the XXII World Veterinary Congress. Perth: MSD AGVET; 1983: 42-48.
  25. Njanja JC, Bell JF, Wescott RB. Apparent lack of toxicity in adult East African goats on parenterally administered ivermectin. Bull Anim Health Prod Afr 1985; 33: 123-127.
  27. Dieterich RA, Craigmill AL. Safety, efficacy, and tissues residues of ivermectin in reindeer. Rangifer 1990; 10: 53-56. http://dx.doi.org/10.7557/2.10.2.794
  29. Pulliam JD, Preston JM. Safety of ivermectin in target animals. En: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag; 1989: 149-161.
  31. Leaning WHD. The efficacy and safety evaluation of ivermectin as a parenteral and oral antiparasitic agent in horses. En: Milne FJ, ed. Proceedings of the 29th Annual Convention of the American Association of Equine Practitioners. Las Vegas: American Association of Equine Practitioners; 1983: 319-328.
  33. Hautekeete LA, Khan SA, Hales WS. Ivermectin toxicosis in a zebra. Vet Human Toxicol 1998; 40: 29-31.
  35. Swor TM, Whittenburg JL, Chaffin MK. Ivermectin toxicosis in three adult horses. J Am Vet Med Assoc 2009; 235: 558-562. http://dx.doi.org/10.2460/javma.235.5.558
  37. Hopkins KD, Marcella KL, Strecker AE. Ivermectin toxicosis in a dog. J Am Vet Med Assoc 1990; 197: 93-94.
  39. Paul AJ, Tranquilli WJ, Seward RL, Todd KS, DiPietro JA. Clinical observations in Collies given ivermectin orally. Am J Vet Res 1987; 48: 684-685.
  41. Tranquilli WJ, Paul AJ, Seward RL. Ivermectin plasma concentration in Collies susceptible to ivermectin induced toxicosis. Am J Vet Res 1989; 50: 769- 770.
  43. Rohrer SP, Evans DV. Binding characteristics of ivermectin in plasma from Collie dogs. Vet Res Commun 1990; 14: 157-165.
  45. Pulliam JD, Seward RL, Henry RT, Steinberg SA. Investigating ivermectin toxicity in Collies. Vet Med 1985; 80: 33-40.
  47. Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in Collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001; 11: 727-733. http://dx.doi.org/10.1097/00008571-200111000-00012
  49. Roulet A, Puel O, Gesta S, Lepage JF, Drag M, Soll M, et al. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 2003; 460: 85-91. http://dx.doi.org/10.1016/S0014-2999(02)02955-2
  51. Mealey KL, Bentjen SA, Waiting DK. Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of Collies from the Northwestern United States. Am J Vet Res 2002; 63: 479-481. http://dx.doi.org/10.2460/ajvr.2002.63.479
  53. Hugnet C, Bentjen SA, Mealey KL. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of Collies from France. J Vet Pharmacol Ther 2004; 27: 227-229. http://dx.doi.org/10.1111/j.1365-2885.2004.00585.x
  55. Houston DM, Parent J, Matushek KJ. Ivermectin toxicosis in a dog. J Am Vet Med Assoc 1987; 191: 78-80.
  57. Hadrick MK, Bunch SE, Kornegay JN. Ivermectin toxicosis in two Australian shepherds. J Am Vet Med Assoc 1995; 206: 1147-1152.
  59. Geyer J, Döring B, Godoy JR, Leidolf R, Moritz A, Petzinger E. Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. J Vet Pharmacol Ther 2005; 28: 545-551. http://dx.doi.org/10.1111/j.1365-2885.2005.00692.x
  61. Kawabata A, Momoi Y, Inoue-Murayama M, Iwasaki T. Canine MDR1 gene mutation in Japan. J Vet Med Sci 2005; 67: 1103-1107. http://dx.doi.org/10.1292/jvms.67.1103
  63. Mealey KL, Munyard KA, Bentjen SA. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet Parasitol 2005; 131: 193- 196. http://dx.doi.org/10.1016/j.vetpar.2005.05.004
  65. Neff MW, Robertson KR, Wong AK, Safra N, Broman KW, Slatkin M, et al. Breed distribution and history of canine MDR1- 1 Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci USA 2004; 101: 11725-11730. http://dx.doi.org/10.1073/pnas.0402374101
  67. Campbell WC. Use of ivermectin in dogs and cats. En: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag; 1989: 245-259.
  69. Lewis DT, Merchant SR, Neer TM. Ivermectin toxicosis in a kitten. J Am Vet Med Assoc 1994; 205: 584-586.
  71. Muhammad G, Abdul J, Khan MZ, Saqib M. Use of neostigmine in massive ivermectin toxicity in cats. Vet Hum Toxicol 2004; 46: 28-29.
  73. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental Pglycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 1998; 12: 457-463. http://dx.doi.org/10.1016/S0890-6238(98)00027-6
  75. Lankas GR, Minsker DH, Robertson RT. Effects of ivermectin on reproduction and neonatal toxicity in rats. Food Chem Toxicol 1989; 27: 523-529. http://dx.doi.org/10.1016/0278-6915(89)90048-3
  77. El-Nahas AF, El-Ashmawy IM. Effect of ivermectin on male fertility and its interaction with P-glicoproteína inhibitor (verapamil) in rats. Environ Toxicol Pharmacol 2008; 26 : 206-211. http://dx.doi.org/10.1016/j.etap.2008.03.011
  79. El-Ashmawy IM, Mandour AA. Studies on the influence of ivermectin on reproductive organs and liver function in male rabbits. En: Third Vet Med Conf. Zagazig: Egypt; 1996.
  81. Brokken ES, Barth D, Foster AG, Pulliam JD, Wallace DH. Ivermectin: a new broad-spectrum antiparasitic agent for swine. En: Leaning W, Siegmund O, Fraser C, eds. Recent developments in the control of animal parasites. Proceedings of the MSD AGVET Symposium at the XXII World Veterinary Congress. Perth: MSD AGVET; 1983: 239-258.
  83. McKissick GE, Sutherland IH, Foix J, Olson G. The safety of ivermectin administered orally to pregnant mares. Equine Vet J 1987; 7: 357-367. http://dx.doi.org/10.1016/S0737-0806(87)80006-0
  85. Daurio CP, Gilman MR, Pulliam JD, Seward RL. Reproductive evaluation of male Beagle dogs and the safety of ivermectin. Am J Vet Res 1987; 48: 1755-1760.
  87. Tanyildizi, S, Bozkurt T. An investigation of the effects of ivermectin on blood serum, semen hyaluronidase activities and spermatological characteristics in sheep. Turk J Vet Anim Sci 2002; 26: 353-357.
  89. Schröder J, Swan GE, Barrick RA, Pulliam JD. Effect of ivermectin on the reproductive potential of breeding rams. J S Afr Vet Assoc 1986; 57: 211-213.
  91. Janett F, Thun R, Ryhiner A, Burger D, Hassig M, Hertzberg H. Influence of Eqvalan® (ivermectin) on quality and freezability of stallion semen. Theriogenology 2001; 55: 785-792. http://dx.doi.org/10.1016/S0093-691X(01)00443-5
  93. Campbell WC, Benz GW. Ivermectin: a review of efficacy and safety. J Vet Pharmacol Ther 1984; 7: 1-16. http://dx.doi.org/10.1111/j.1365-2885.1984.tb00872.x
  95. Herd RP, Donham JC. Efficacy of ivermectin against Onchocerca cervicalis microfilarial dermatitis in horses. Am J Vet Res 1983; 44: 1102-1105.
  97. Karns PA, Luther DG. A survey of adverse effects associated with ivermectin use in Louisiana horses. J Am Vet Med Assoc 1984; 185: 782-783.
  99. Campbell WC, Leaning WHD, Seward RL. Use of ivermectin in horses. En: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag; 1989: 234-244.
  101. Breukink HJ, Eysker M. Intravenous administration of Ivomec® in horses. Tijdschr Diergeneeskd 1995; 120: 113- 114.

Información

SCImago Journal & Country Rank

0.6
2020CiteScore
 
 
28th percentile
Powered by  Scopus
Redib Widget
Tutoriales

Autores:

¿Cómo enviar un artículo?

Par evaluador:

¿Cómo evaluar un artículo?

Palabras clave

Código QR

Número actual

Perfil de Google Scholar

Más leídos en los últimos 30 días

Sistema OJS 3.4.0.3 - Metabiblioteca |